Owlstone Medical Ltd

Owlstone Medical is a UK-based biotechnology company pioneering breath biomarker analysis for non-invasive disease detection and precision medicine. The company develops Breath Biopsy® technology and related research products and services that enable comprehensive analysis of volatile organic compounds (VOCs) from multiple sample types, ranging from in vitro cell culture to human breath samples. Clinical applications span oncology (lung cancer, multi-cancer early detection), respiratory disease (cystic fibrosis, Pseudomonas aeruginosa detection), gastrointestinal disorders, liver disease, and microbiome analysis. Owlstone's Breath Biopsy VOC Atlas® is a proprietary database of volatile organic compound biomarkers supporting research and clinical validation. The company collaborates with major academic medical centers (Mayo Clinic, Cleveland Clinic, Brigham and Women's Hospital, NHS), pharmaceutical partners (AstraZeneca, Boehringer Ingelheim, MedImmune), and cancer research organizations (Cancer Research UK). Recent funding includes a $49.1 million ARPA-H award for developing at-home multi-cancer early detection tests targeting Stage I detection of 30+ solid tumors, and a Cystic Fibrosis Foundation investment for breath testing of bacterial infections. Owlstone maintains an active FDA research collaboration agreement for developing analytical methods to identify specific chemicals in gaseous mixtures. The company is positioned in the diagnostic software and decision-support space, providing tools for biomarker identification and clinical validation rather than manufacturing traditional medical devices.